Singapore markets close in 4 hours 39 minutes
Straits Times Index
3,294.94 +22.22 (+0.68%) Nikkei
38,407.40 +855.24 (+2.28%) Hang Seng
17,110.21 +281.28 (+1.67%) FTSE 100
8,044.81 +20.94 (+0.26%) Bitcoin USD
66,687.16 +154.03 (+0.23%) CMC Crypto 200
1,435.13 +20.37 (+1.44%)
Gilead Sciences, Inc. (GILD.VI)
Vienna - Vienna Delayed price. Currency in EUR
Add to watchlist
At close: 05:32PM CEST
| Previous close | 63.11 |
| Open | 62.90 |
| Bid | 62.90 x 0 |
| Ask | 63.03 x 0 |
| Day's range | 62.90 - 62.97 |
| 52-week range | 61.92 - 79.86 |
| Volume | |
| Avg. volume | 6 |
| Market cap | 78.522B |
| Beta (5Y monthly) | 0.20 |
| PE ratio (TTM) | 14.89 |
| EPS (TTM) | 4.23 |
| Earnings date | 25 Apr 2024 |
| Forward dividend & yield | 2.85 (4.52%) |
| Ex-dividend date | 14 Mar 2024 |
| 1y target est | N/A |
ZacksIncyte (INCY) Earnings Expected to Grow: Should You Buy?
Incyte (INCY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksGilead (GILD) Gears Up to Report Q1 Earnings: What to Expect?
Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports first-quarter 2024 results.
ZacksInsights Into Gilead (GILD) Q1: Wall Street Projections for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for Gilead (GILD), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.
© 2024 Yahoo. All rights reserved.